Amedisys Reports Second Quarter 2020 Financial Results - Reissues 2020 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Amedisys (AMED) Tops Q2 EPS by 53c, Revs Beat
July 28, 2020 4:11 PM EDTAmedisys (NASDAQ: AMED) reported Q2 EPS of $1.34, $0.53 better than the analyst estimate of $0.81. Revenue for the quarter came in at $485 million versus the consensus estimate of $469.13 million.
Paul B. Kusserow, President and Chief Executive Officer stated, I am very proud of our second quarter results which have allowed us to reissue our... More
